Journal article
Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses
Abstract
BackgroundImmuno-oncology, and in particular, check-point inhibitors (CPIs), have led to a paradigm shift in the field of cancer care. The cost of new drug development is high, and many novel agents in oncology are significantly more expensive than older agents. Therefore, healthcare funders have factored measures of cost-effectiveness into decisions concerning drug reimbursement and incorporation of new agents into treatment algorithms. The …
Authors
Wang Y; Camateros P; Smith D; Dawe D; Ellis P
Journal
Systematic Reviews, Vol. 8, No. 1,
Publisher
Springer Nature
Publication Date
December 2019
DOI
10.1186/s13643-019-1047-z
ISSN
2046-4053